# US 2022/0031811 A1 · Insulin glargine/lixisenatide fixed ratio formulation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2022/0031811 A1
- Document ID: US20220031811A1
- Status: Published application
- Kind: A1
- Application number: 17/306,184
- Filed: 2021-05-03
- Published: 2022-02-03
- Earliest claimed: 2013-06-17
- Assignees: Sanofi-Aventis Deutschland GmbH
- Applicants: Sanofi-Aventis Deutschland GmbH
- Inventors: Elisabeth Souhami; Louise Silvestre
- Web page: https://patentgrep.com/patent/US20220031811A1

## CPC

- A61K 38/28: Insulins
- A61K 38/26: Glucagons
- A61P 3/00: Drugs for disorders of the metabolism (of the blood or the extracellular fluid A61P7/00)
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention refers to a pharmaceutical composition comprising (a) lixisenatide or/and a pharmaceutically acceptable salt thereof, and (b) insulin glargine or/and a pharmaceutically acceptable salt thereof, wherein the compound (b) and compound (a) are present in a fixed ratio.

## Claims

### Claim 1

A pharmaceutical composition comprising
(a) lixisenatide or a pharmaceutically acceptable salt thereof, and
(b) insulin glargine or a pharmaceutically acceptable salt thereof,
wherein the compound (b) and compound (a) are present in a ratio of about 1.6 to about 2.4 U of compound (b) per μg of compound (a).

### Claim 2 (depends on 1)

The composition of claim 1, wherein the concentration of compound (a) is in the range of 40-60 μg/ml, and wherein the concentration of compound (b) is in the range of 64-144 U/ml.

### Claim 3 (depends on 2)

The composition of claim 2, wherein the concentration of compound (a) is not 55.56 μg/mL, 51.28 μg/mL, 47.62 μg/mL, 44.44 μg/mL, or 41.67 μg/mL.

### Claim 4 (depends on 1)

The pharmaceutical composition of claim 1, wherein the compound (b) and compound (a) are present in a ratio of about 2 U of compound (b) per μg of compound (a).

### Claim 5 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered at a dose of 0.25 to 1.5 U/kg body weight insulin glargine.

### Claim 6 (depends on 1)

The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is administered at a dose of 0.05 to 0.5 μg/kg body weight lixisenatide.

### Claim 7 (depends on 1)

The pharmaceutical composition of claim 1, further comprising (c) metformin or pharmaceutically acceptable salt thereof.

### Claim 8 (depends on 1)

The pharmaceutical composition of claim 1, further comprising a pharmaceutically acceptable carrier.
